DGAP-News

Gerresheimer AG: Gerresheimer with positive start to the financial year 2021

DGAP-News: Gerresheimer AG / Key word(s): Quarterly / Interim Statement Gerresheimer AG: Gerresheimer with positive start to the financial year 2021 08.04.2021 / 07:06 The issuer is solely responsible for the content of this announcement. Gerresheimer with positive start to the financial year 2021

- Organic revenue growth of 3.1 % in core business

- Strong development in High Value Solutions: Focus on Biological Solutions pays off

- Adjusted EBITDA increases organically by 7.0 % in core business

- Adjusted earnings per share rise organically by 29.3 % to EUR 0.57

- Guidance confirmed for the financial year 2021

Duesseldorf, April 8, 2021 - "We got off to a good start in the financial year," said Dietmar Siemssen, CEO of Gerresheimer AG. "Our high value products and solutions for biotech and pharma companies saw significant growth in the first quarter. The order books are full. We are well on our way to achieving our targets for 2021. The achievements which are now becoming visible, confirm the effectiveness of our growth strategy, which will continue to roll out systematically."

In the first quarter of 2021, Gerresheimer Group generated revenues of EUR 303m. Revenues in core business increased organically by 3.1% year on year. The Plastics & Devices Division grew organically by 3.0% in the first quarter of 2021, thanks in particular to the syringes business and the demand for pharmaceutical plastic packaging. Currency-adjusted sales were up 3.2% year on year in the Primary Packaging Glass Division, even though the cosmetics business in the Moulded Glass Business Unit continued to feel the negative effects of the Covid-19 pandemic. The pharma business benefited in the first quarter from growing demand for high value solutions and products such as Gx RTF syringe systems, Gx Elite Glass and Gx RTF Vials, particularly for biopharmaceuticals.